Immix Biopharma, Inc. — Form 10-Q
Filed August 7, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 52/100
What the filing says
Immix amended employment agreements for Ilya Rachman (CEO) and Gabriel Morris (CFO, via Alwaysraise LLC) effective August 7, 2026. Both now receive $515,000 annual base salary/fee (Rachman direct; Morris via management services agreement), plus 50% targeted bonus eligibility ($257,500 each) and equity awards at Compensation Committee discretion. Prior compensation amounts not disclosed in this filing.
Why this rating
~$1.4M annual comp cost (~4% of $35.7M market cap) for two key executives; material but not business-altering. No equity dilution or financial distress signal disclosed.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.